Black Beret Life Sciences, LLC

Since its inception, Black Beret Life Sciences has led research for treatments based on regenerative medicine for cancer, diabetes, neurodegeneration, osteoarthritis, and other conditions related to aging.

Dr. Bosarge currently serves as Founder and Chairman of Black Beret Life Sciences. Dr. Marc S. Penn, MD, PhD, FACC, a leading physician, scientist and entrepreneur, serves as Chief Executive Officer of BBLS and leads a team specializing in diverse medical disciplines. As CEO, Dr. Penn oversees the life science investments of the Bosarge Family Office in the areas of regenerative medicine, anti-aging and immune therapy. Black Beret Life Sciences supports research at a number of institutions, including MD Anderson Cancer Center and Rutgers University, as well as manages and/or invests in the following:

Okyanos Center for Regenerative Medicine – A state-of-the-art medical facility in Freeport, Bahamas, that offers regenerative medicine treatment for orthopedic, neurologic, cardiac and other chronic conditions using enzyme-derived Stromal Vascular Fraction (SVF) from the patient's own fat.  Okyanos is the flagship for Black Beret Life Sciences’ development of an international stem cell treatment network based on patient safety and transparency to further the global reach of regenerative medicine. Visit: Okyanos

Tissue Genesis, LLC – Tissue Genesis offers best-in-class, clinical grade cell therapy solutions. Its state-of-the-art Icellator® is a high-performance, point-of-care device that efficiently extracts adult stem cells from a small sample of autologous adipose tissue in a fully enclosed and automated process. Manufactured under cGMP to the highest ISO 13485 and FDA standards, the Icellator® requires no human intervention and provides yields of stromal vascular fraction that are sufficiently pure to allow for intravenous infusion in an hour or less. Founded in 2001, TG is part of the Black Beret Life Sciences, LLC portfolio of companies dedicated to accelerating life sciences through novel therapeutics and commercial innovations. Tissue Genesis’ Icellator® is approved for use by medical regulatory authorities in South Korea, the Ukraine and the Bahamas, with ongoing FDA-cleared trials in the USA for multiple indications of chronic disease. Visit: Tissue Genesis

Advanced Regen Medical Technologies, LLC – Dedicated to making advances in restoring function to stem cells of aged patients, the company focuses on the association between aging and the loss of our body’s inherent ability to maintain and repair tissue. In blood, diminishing stem cell function is a contributing factor for age-related risk of infection and cancer. The restoration technology being developed at Advanced Regen has demonstrated that loss of aged stem cell function can be restored through exposure to soluble molecular signals released by stem cells from young, healthy individuals. This approach is rooted in the century-old concept of heterochronic parabiosis, whereby exposure of aged tissues to young factors can extend organismal lifespan and improve aged tissue function.

Affigen, LLC – The Company uses "precision design" to develop tumor identifying therapies to treat cancer.  Affigen’s focus is on driving powerful immune responses against molecules unique to cancer, while minimizing the risk of damage to healthy tissues.  Leveraging highly automated process engineering and personal scale biologics manufacturing, Affigen develops new therapies for previously “undruggable” targets. In effect, Affigen uses cancer’s “Achille’s Heel”: the proteins which distinguish tumor cells from normal cells, that can target tumor cells for destruction with extreme sensitivity and precision.  As a translational-stage company, Affigen’s therapeutics’ development is done with rapid clinical adoption in mind, and in close collaboration with an extensive expert network of world-class academic collaborators.  Affigen's team houses deep expertise in immuno-oncology, mass-personalized biomolecular engineering and complex therapeutic development. Visit: Affigen

Diasome Pharmaceuticals, Inc. – Patients with Type I diabetes are at risk of morbidity and mortality due to low blood sugar levels. Diasome is a clinical stage company developing novel therapies to enhance blood sugar control without putting the patient at risk for low blood sugars.  The company is also developing novel strategies for the prevention and treatment of Type II diabetes. Visit: Diasome

Black Beret Life Sciences is also actively working to expedite FDA approval of safe and effective cellular therapies in the U.S.  As part of this effort, Dr. Bosarge contributed to the Bipartisan Policy Center’s July 2015 report, Advancing Medical Innovation for a Healthier America. The report, which included a recommendation on advancing regenerative cellular therapies, proposed a series of viable legislative actions that Congress could take to help streamline the process by which safe and effective medical products are developed and delivered to patients. With cellular therapy holding enormous promise for future cures and treatments, Black Beret Life Sciences is committed to doing what it can to help the field reach its full medical potential by creating a more efficient regulatory framework in the U.S.

Black Beret Life Sciences, LLC is owned by a family trust and is headquartered in Houston, Texas.